New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Overview of attention for article published in Frontiers in oncology, September 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet

twitter: 4 X users

Citations

dimensions_citation: 105 Dimensions

Readers on

mendeley: 180 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Mirati Therapeutics, Inc.: Cracking KRAS Is Harder Than It Looks

Seeking Alpha, 21 Apr 2020

We are short shares of Mirati Therapeutics, a $4.6bn clinical-stage biopharmaceutical company whose lead drug candidate, MRTX-849…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.